Systematic structure-activity study on potential chaperone lead compounds for acid α-glucosidase.

Area of Science:

• Biochemistry
• Pharmacology
• Genetics

Background:

• Acid α-glucosidase (GAA) is a lysosomal enzyme and a target for Pompe disease treatment.
• Pharmacological chaperones are emerging as a therapeutic strategy for lysosomal storage disorders (LSDs).

Purpose of the Study:

• To systematically study inhibitors of GAA as potential lead compounds for chaperone development.
• To understand the molecular mechanisms underlying GAA-ligand interactions for drug design.

Main Methods:

• Systematic screening of thirteen GAA inhibitors.
• In vitro binding assays at varying pH.
• In silico molecular docking to a human GAA homology model.
• Cellular assays to assess lysosomal localization of GAA variants.

Main Results:

• Identified thirteen lead compounds for GAA chaperone development.
• Verified ligand binding to GAA at low and neutral pH.
• Discovered that ligand charge, hydroxyl group positioning, and active site flexibility are crucial for binding affinity.
• Observed increased lysosomal localization of GAA variants in cells treated with these compounds.

Conclusions:

• Established a framework for designing specific pharmacological chaperones for human GAA.
• Provided a basis for developing novel therapeutics for Pompe disease.
• Highlighted the importance of ligand charge and specific interactions for chaperone efficacy.